IBA strengthens its leadership in the Chinese proton therapy market
Louvain-La-Neuve, Belgium, 15 July 2019 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the arrival and rigging of the 220-ton Cyclone®230 cyclotron at the Proton International Guangzhou Center located in Guangzhou, Guangdong Province, China. This innovative cancer center led by the Guangdong Hengjian Nuclear Medical Industry Co., Ltd will be equipped with IBA’s Proteus®PLUS solution, optimized for best-in-class treatment with three-gantry treatment rooms with Pencil Beam Scanning (PBS), integrated Cone Beam CT Image Guidance (CBCT) and ultra-high dose rate capability for flash irradiation research.
Mr. Han Lianhe, Chairman of Hebei United Medical Management, Mr. Wang Wei, Board of Director of Guangdong Hengjian Investment and several other investors and government officials were also present, such as the official delegate from the Belgium Embassy with Mr Joris Salden, the Consul General of Belgium in Guangzhou and Ms Catherine Huang, commercial secretary. In total, more than 100 people participated in this exciting event well covered by local news and press. This type of event underscores the enthusiasm of people who work for IBA, a company that provides exemplary customer service and most importantly, contributes to improving people’s lives.
To date, IBA has sold 55 proton therapy centers worldwide, with five of them located in mainland China.
Olivier Legrain, Chief Executive Officer of IBA, commented: “We are proud to deliver this important installation milestone to a facility of such quality and importance in South China. IBA’s experience in proton therapy makes us ideally suited to partner to bring proton therapy to more patients across China who will benefit from this leading-edge cancer treatment. With 50 per cent of the market share and the rigging of a new center in China, IBA increases its leadership in potentially the largest radiotherapy market in the world.”
Mr Han Lianhe, Chairman of Hebei United Medical Management, commented: “Today, the rigging ceremony marks a milestone in the construction of this proton therapy center. Here in Guangzhou we are creating one of the most advanced oncology therapy center in Asia, all thanks to IBA’s technological leadership in proton therapy.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
About Guangdong Hengjian Nuclear Medical Industry
Guangdong Hengjian Nuclear Medical Industry Co., Ltd (GHNMIC) is the first company in China focusing on the development and expansion of proton therapy in China under the spirit of 'Government Supported, Corporatized Management and Market Oriented. From 2013, GHNMIC and Cancer Center of Sun Yat-sen University (CCSYU started working together on the first proton project, namely, Guangdong Hengjian Proton Medical Device Demonstration Project (Project). GHNMIC is the Investment Company of Project.
About Proton International Guangzhou Center
Proton International Guangzhou Center (PIGC) is the user of the project. PIGC is establishing itself as a national cancer center and world-class cancer treatment institute in accordance with Grade III standards of oncology hospital. PIGC takes the accurate and advanced proton therapy as its core technology and masters conventional radiological diagnosis and treatment techniques. The equipped devices include IBA’s Proteus®PLUS, PET-CT, MRI, CT, electron Linacs and ToMography systems etc. PIGC could provide medical solutions for patients, including surgery, chemotherapy, radiotherapy, biological immunotherapy and Chinese medicine rehabilitation treatment. Based on patients’ illness, physical conditions, physiologies and families, PIGC makes the most personalized solutions and provides the best services to satisfy patients with the most efforts.
For further information, please contact:
IBA
Aymeric Harmant
Global Marketing Director
+32 10 203 796